Skip to main content
Kexing Biopharm logo

Kexing Biopharm — Investor Relations & Filings

Ticker · 688136 ISIN · CNE100006ZG6 LEI · 529900Z34Q1M9A907771 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 756 across all filing types
Latest filing 2022-04-18 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688136

About Kexing Biopharm

https://www.kexingbiopharm.com/

Kexing Biopharm is an innovative biopharmaceutical enterprise engaged in the research, development, production, and sales of recombinant protein drugs and micro-ecological preparations. The company focuses on developing treatments for therapeutic areas including kidney diseases, oncology, antiviral therapy, autoimmune disorders, metabolic diseases, and degenerative diseases. A key product in its portfolio is Erythropoietin Injection. Kexing Biopharm maintains a comprehensive quality system that aligns with international standards, covering the entire drug lifecycle from production and quality control to release and transportation, ensuring the continuous and stable manufacturing of safe and effective medicines.

Recent filings

Filing Released Lang Actions
2021年度内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled as an "内部控制审计报告" which translates to "Internal Control Audit Report". It is issued by a certified public accounting firm and addresses the effectiveness of internal controls over financial reporting as of December 31, 2021. The document includes audit opinions and references to auditing standards and responsibilities. It is a standalone audit report focusing on internal control effectiveness rather than a full annual report or interim financial statements. The length is about 4750 characters, which is sufficient for a detailed audit report. There is no indication that this is merely an announcement or certification letter. Therefore, this document fits the category of an Audit Report / Information (AR). FY 2021
2022-04-18 Chinese
关于提请股东大会授权董事会办理以简易程序向特定对象发行股票相关事宜的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from the board of directors of 科兴生物制药股份有限公司 regarding a proposal to authorize the board to handle a simplified procedure for issuing shares to specific investors. It details the authorization matter, issuance conditions, pricing, use of proceeds, and other procedural aspects. The document is a formal announcement about a capital raising activity involving issuance of new shares to specific parties, not the actual issuance report or financial statements. It is not a full financial report, earnings release, or regulatory certification. The content fits the category of Capital/Financing Update (CAP) as it provides detailed information about a financing activity and share issuance authorization.
2022-04-18 Chinese
2021年度利润分配预案公告
Notice of Dividend Amount Classification · 95% confidence The document is a profit distribution plan announcement for the fiscal year 2021 by 科兴生物制药股份有限公司. It details the proposed cash dividend per share, the total dividend amount, the rationale for the dividend payout ratio, and the company's financial performance and future funding needs. It also includes the board of directors' meeting resolutions, independent directors' opinions, and supervisory board opinions. The document is relatively short (2865 characters) and focuses on the dividend distribution plan rather than presenting full financial statements or comprehensive annual financial data. It is not the full Annual Report (10-K) or an Interim Report (IR), nor is it a simple announcement of report publication. The content aligns with a Notice of Dividend Amount (DIV) filing, which announces dividend amounts, payment dates, and related details for shareholders.
2022-04-18 Chinese
自愿披露关于签署英夫利西单抗独家推广服务协议的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by 科兴生物制药股份有限公司 regarding the signing of an exclusive promotion service agreement for a pharmaceutical product (英夫利西单抗) with another company. It details the terms of the agreement, payment structure, product information, and risk factors. The document is an announcement of a business cooperation agreement and does not contain financial statements, audit information, or regulatory certifications. It is not a report, earnings release, or management discussion. The content fits best under a general regulatory announcement category about a corporate transaction or agreement. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length is under 5,000 characters, but it is not merely announcing the publication of a report; it is itself the announcement of a business agreement.
2022-03-31 Chinese
关于自愿披露对外投资设立控股子公司的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by 科兴生物制药股份有限公司 regarding its voluntary disclosure of an external investment to establish a holding subsidiary company. It details the investment amount, shareholder structure, governance, and risks associated with the new joint venture. The document is an announcement of a corporate investment activity, not a financial report, earnings release, or regulatory filing of financial results. It does not contain financial statements or detailed financial analysis. The document length is 3424 characters, which is relatively short and consistent with an announcement rather than a full report. The content focuses on capital investment and company structure related to financing and investment activities. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2022-03-14 Chinese
2021年度业绩快报公告
Earnings Release Classification · 95% confidence The document is titled as a "2021年度业绩快报公告" which translates to "2021 Annual Performance Express Announcement". It contains preliminary financial data for the year 2021, including revenue, profit, net income, earnings per share, and asset information. The data is explicitly stated as preliminary and unaudited, with a note that the final audited data will be in the company's 2021 annual report. The document is relatively short (1737 characters) and serves as a quick summary or earnings flash rather than a full detailed report. This matches the characteristics of an Earnings Release (ER), which is an initial announcement of quarterly or annual financial results with key highlights only. It is not a full Annual Report (10-K) or Interim Report (IR) because it lacks comprehensive financial statements and detailed analysis. It is also not a Report Publication Announcement (RPA) because it contains actual preliminary financial data, not just a notice of report availability. FY 2021
2022-02-27 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.